Volume | 46,877 |
|
|||||
News | - | ||||||
Day High | 11.25 | Low High |
|||||
Day Low | 10.70 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Skye Bioscience Inc | SKYE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.00 | 10.70 | 11.25 | 10.94 | 11.32 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,648 | 46,877 | $ 10.96 | $ 513,904 | - | 10.50 - 17.6473 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:03 | formt | 285 | $ 10.94 | USD |
Skye Bioscience Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
359.55M | 28.07M | - | 152k | -37.65M | -1.34 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Skye Bioscience News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SKYE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.72 | 12.16 | 10.50 | 11.60 | 66,895 | -0.78 | -6.66% |
1 Month | 12.58 | 13.44 | 10.50 | 11.88 | 55,760 | -1.64 | -13.04% |
3 Months | 13.50 | 17.6473 | 10.50 | 13.22 | 60,467 | -2.56 | -18.96% |
6 Months | 13.50 | 17.6473 | 10.50 | 13.22 | 60,467 | -2.56 | -18.96% |
1 Year | 13.50 | 17.6473 | 10.50 | 13.22 | 60,467 | -2.56 | -18.96% |
3 Years | 13.50 | 17.6473 | 10.50 | 13.22 | 60,467 | -2.56 | -18.96% |
5 Years | 13.50 | 17.6473 | 10.50 | 13.22 | 60,467 | -2.56 | -18.96% |
Skye Bioscience Description
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease. |